Changes in Beneficial Ownership · 4
Nkarta, Inc.
NKTXNASDAQEQUITYCurrent
Changes in Beneficial Ownership
Structured filing — 4
ownership.xml
Filing details
- Report period
- 2026-06-10
- Issuer
- Nkarta, Inc.
- Issuer CIK
- 0001787400
- Trading symbol
- NKTX
Reporting owner 1
- Name
- PATTERSON LEONE D
- Reporting owner CIK
- 0001233539
- Relationship
- Director
- Address
- C/O NKARTA, INC., 1150 VETERANS BOULEVARD, SOUTH SAN FRANCISCO, CA, 94080
Derivative transactions
| Security | Conversion / exercise price (USD) | Transaction date | Code | Amount | A / D | Price (USD) | Exercisable | Expires | Underlying security | Underlying shares | Owned after | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy) | 2.46 | 2026-06-10 | A · Form 4 | 37,000 | A | 0 | [F1] | 2036-06-09 | Common Stock | 37,000 | 37,000 | D |
Table key
- A · Form 4
- Acquisition by grant, award or otherwise under Rule 16b-3(d)
- A
- Acquired
- D
- Direct
Footnotes
- F1
- All shares subject to the option vest 100% on the first to occur of (i) June 10, 2027 or (ii) the day immediately preceding the first annual meeting of the Issuer's stockholders to occur after the date of grant of the award. Each grant, to the extent outstanding and otherwise unvested, will become fully vested should a "change in control" of the Issuer occur (as described in the applicable award agreement) or upon the Reporting Person's separation from service with the Issuer due to the Reporting Person's death or "disability" (as described in the applicable award agreement).↩ 1
Signature 1
- Signed
- /s/ Bridgette Housley, as Attorney-in-Fact
- Date
- 2026-06-11
Company context
Nkarta is a clinical-stage biotechnology company advancing the development of allogeneic, off-the-shelf natural killer (NK) cell therapies for people living with autoimmune diseases. By harnessing the power of the innate immune system to eliminate pathogenic B cells driving the autoimmune response, Nkarta is advancing novel cell therapies engineered for deep therapeutic impact. The on-demand availability and outpatient dosing of our CAR-NK cells enables a broad population of patients with different autoimmune conditions to conveniently access NK cell therapy in community health settings. For more information, please visit the company’s website at www.nkartatx.com.